Kymera Therapeutics News and Activities
Presence
Kymera Therapeutics develops medicines that target and degrade disease-causing proteins. Its services and drug candidates support patients, healthcare providers, and pharmaceutical partners in cancer, immune, and inflammatory diseases.
Kymera Therapeutics products and services overview:
- Protein degrader drugs
- Drug discovery
- Oncology therapies
- Immunology therapies
- Inflammation treatments
- Research partnerships
Revenue: ~$194 million
Employees: 270
Headquarters: Watertown, United States (USA)
Kymera Therapeutics is one of the...
Kymera Therapeutics is a company listed under the stock ticker KYMR (US).
Executives
View the org chart displaying its 24 main executives
Most searched biographies at Kymera Therapeutics
- Nello Mainolfi, Director, President and Chief Executive Officer
- Gorjan Hrustanovic, Director
- Pamela Esposito, Director
Create your alert
to follow the executive moves at Kymera Therapeutics.
Biotechnology
Kymera Therapeutics has 2,406 competitors including Eurofins (Luxembourg), Lonza (Switzerland) and BioNTech (Germany).
Popular M&A news in Biotechnology
- Laboratoire Servier has announced the acquisition of Edgewise Therapeutics (posted on June 4 2026).
- Oak Hill Bio has just announced a $33 Million fundraising (posted on June 4 2026).
- IMU Biosciences has just announced a $53 Million fundraising (posted on June 3 2026).
Popular contacts in Biotechnology
News
Press releases by Kymera Therapeutics
- Kymera Therapeutics Announces Publication of Phase 1 Trial Results for KT-474 (SAR444656), a First-in-Class IRAK4 Degrader, in Nature Medicine | Kymera Therapeutics, Inc.
- Press Releases | Kymera Therapeutics, Inc.
- Kymera Therapeutics Receives U.S. FDA Fast Track Designation for KT-333, a First-in-Class, Investigational STAT3 Degrader for the Treatment of Relapsed/Refractory Cutaneous T-Cell Lymphoma and Relapsed/Refractory Peripheral T-Cell Lymphoma | Kymera Therap
- Kymera Therapeutics Presents Preclinical Data Demonstrating Activity of MDM2 Degraders in Acute Myeloid Leukemia and Merkel Cell Carcinoma | Kymera Therapeutics, Inc.
- Kymera Therapeutics to Participate in Upcoming September Investor Conferences | Kymera Therapeutics, Inc.
- Kymera Therapeutics to Report Second Quarter 2022 Results on August 9 | Kymera Therapeutics, Inc.
- Press Releases | Kymera Therapeutics, Inc.
- Press Releases | Kymera Therapeutics, Inc.
- Kymera Therapeutics Strengthens Board of Directors with Appointment of People and Business Leader Leigh Morgan | Kymera Therapeutics, Inc.
- Kymera Therapeutics Doses First Patients in Phase 1 Oncology Trials of STAT3 and IRAKIMiD Degraders KT-333 and KT-413 | Kymera Therapeutics, Inc.
- View more press releases Close
Social media about Kymera Therapeutics
- Kymera Therapeutics on Wikipedia, Google News & Yahoo Finance
- Kymera Therapeutics on LinkedIn, X (Twitter) & YouTube
